103 results about "Discoid lupus erythematosus" patented technology

The invention discloses an American cockroach medicinal composition for curing ulcers or ulcerative inflammation. The medicinal composition is mainly prepared from an active ingredient mixture prepared by mixing an American cockroach extract and montmorillonite powder. The weight part ratio of the American cockroach extract to the montmorillonite powder is equal to 0.8-1.2:0.5-6. A preparation method of the American cockroach medicinal composition for curing the ulcers or the ulcerative inflammation comprises the following steps of: preparing the American cockroach extract, mixing active ingredients, and preparing medicaments. The medicinal composition has simple preparation method, fully exerts effects of the American cockroach extract, and has obvious effects of effectively curing diseases such as oral ulcers, recurrent aphthous ulcers, oral lichen planus, oral mucosal injury (behcet disease, herpes simplex, leukoplakia, discoid lupus erythematosus, hand-foot-and-mouth disease, scalds, chemotherapy, radiotherapy and the like) caused by various reasons, reflux esophagitis, eophageal ucers, radiation esophagitis, ulcerative colitis, radiation proctitis, and diarrhea, and hematochezia with mucosal injury, and the like.

The invention discloses an epitope of systemic lupus erythematosus and an application thereof, belonging to the technical field of immunology diagnosis. The epitope is a polypeptide of which the amino acid sequence is shown as a sequence table SEQ ID NO:1. As proved by ELISA (Enzyme-Linked Immunosorbent Assay) detection and the serum reaction condition of a patient, the epitope polypeptide can be specifically combined with IgG (Immunoglobulin G) in the serum of the patient without reacting with the serum of a healthy person. The epitope polypeptide can be used for preparing a medicament for diagnosing systemic lupus erythematosus.

Provided is a treating method for circular RNA in systemic lupus erythematosus. The treating method comprises the following steps that a systemic lupus erythematosus group, a rheumatoid arthritis group and a normal control group are set, each group comprises a plurality of parts of whole blood samples which are detached from the human body of different human bodies, , peripheral blood mononuclear cells are obtained by separating correspondingly; total RNA in all peripheral blood mononuclear cells is extracted correspondingly; ribonucleic acid labeling and chip hybridization are conducted; and the fluorescence intensity of a chip after hybridization is scanned, the obtained chip scanning result is analyzed, and circular RNA differently expressed between the systemic lupus erythematosus group and the normal control group as well as the systemic lupus erythematosus group and the rheumatoid arthritis group is sieved. According to the treating method for the circular RNA in the systemic lupus erythematosus, circ RNA abnormally expressed by the systemic lupus erythematosus is obtained and can serve as a potential diagnostic marker for the systemic lupus erythematosus, and sufficient theoretical basis for studying pathogenesis of the systemic lupus erythematosus can be further provided.

The invention relates to a diagnostic marker for systemic lupus erythematosus, and in particular discloses application of a reagent for specific detection of high mannose type N-linked carbohydrate chain level in a serum antibody to preparation of a diagnostic tool for diagnosis and / or prognosis assessment of systemic lupus erythematosus. The increase of the high mannose type N-linked carbohydrate chain level in the serum antibody is closely related to the occurrence of systemic lupus erythematosus. Therefore, the diagnostic marker can be used for early diagnosis and / or prognostic assessment of systemic lupus erythematosus, and further can be used for guiding treatment of systemic lupus erythematosus.

The invention relates to a preparation method of a medical intermediate 4,7-dichloroquinoline. The 4,7-dichloroquinoline is an important intermediate of a medicine hydroxychloroquine sulfate for treating discoid lupus erythematosus and systemic lupus erythematosus. The preparation method comprises the following steps: performing hydrolysis and acid adjustment on 4-hydroxyl-7-chlorine-quinoline-3-carboxylic acid ethyl ester by using 10% sodium hydroxide solution to prepare 4-hydroxyl-7-chlorine-quinoline-3-carboxylic acid; performing decarboxylation to produce 4-hydroxyl-7-chloroquinoline; and chlorinating the 4-hydroxyl-7-chloroquinoline by using phosphorus oxychloride to obtain 4,7-dichloroquinoline crude products; and performing one-step refining to obtain the products. The purity of the prepared products is more than or equal to 99% and the total yield of the products is more than or equal to 70%; raw materials are easily available; the process is simple; the yield and the purity are high in each step; and the preparation method is suitable for industrialized production.

The present invention provides a heterocyclic compound having a TLR7, TLR9, TLR7 / 8, TLR7 / 9 or TLR7 / 8 / 9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

The invention relates to a stage protein expression difference spectrum model for systemic lupus erythematosus (SLE), and by comparing the differences between proteomics of an SLE patient in an active stage and a stationary stage and a normal person or a rheumatoid arthritis patient, the protein expression difference spectrum of the systemic lupus erythematosus is obtained, which is important to clinical diagnosis and disease investigation of the SLE. Moreover, the invention also relates to a construction method of the stage protein expression difference spectrum model for the systemic lupus erythematosus, and by adopting the isobaric tags for relative and absolute quantification (iTRAQ) multiple labeling tandem mass spectrum technology, protein of a human peripheral blood mononuclear cell can be effectively identified and quantified relatively; and by adopting the technology, the stage protein expression difference spectrum model of the human peripheral blood mononuclear cell of the SLE patient can be obtained, which helps to further clarify the pathogenesis of the SLE and provide new ways for diagnosing and treating the SLE.

Covalent Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. A method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

Proline compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

Pyrrole compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

The invention relates to a method of using HLA-G positive mesenchymal stem cells to treat systemic lupus erythematosus, in particular to, on one hand, a method of preparing human leukocyte antigen-G positive mesenchymal stem cells for treating systemic lupus erythematosus. The system includes following steps: (1), performing isolated culture on HLA-G+umbilical card mesenchymal stem cells; (2), cryopreserving the HLA-G positive mesenchymal stem cells; (3), resuscitating the HLA-G positive mesenchymal stem cells. Higher than 90% of the mesenchymal stem cells prepared by the method is positive to human leukocyte antigen-G. It has been already found that the HLA-G+umbilical card mesenchymal stem cells have excellent effect on treating systemic lupus erythematosus.

The invention discloses a pharmaceutical composition for treating oral ulcer and Behcet syndrome, which is made from the following components: 60 to 80 percent of flos lonicerae extract, 19.8 to 34 percent of glycyrrhiza glabra extract, 0.1 to 3 percent of Chan-Su extraction and 0.1 to 3 percent of common threewingnut root extract. The dosage form of the pharmaceutical composition can be tablet, powder, sticking film, spraying agent and the like and the pharmaceutical composition can be applied to treating oral ulcer, sore throat, Behcet syndrome and other diseases. The pharmaceutical composition can relieve inflammation and alleviate pain and is mainly applied to treating autoinmmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and immunity glomerular nephritis clinically. In addition, the common threewingnut root is clinically applied to treating Behcet syndrome according to reports.

The invention provides a product for treating systemic lupus erythematosus and rheumatism and a preparation method thereof, and belongs to the field of Chinese patent medicine and pharmacy technology thereof. The invention is characterized in that the product is obtained from common submerged fermentation of a water extract of the following traditional Chinese medicines and a morel mother strain: 20-40 parts of radix clematis, 20-40 parts of Ligusticum wallichii, 20-40 parts of madder, 20-40 parts of late silkworm excrement, 20-40 parts of red adzuki beans, 20-40 parts of angelica, 20-40 parts of cinnamon and 20-40 parts of semen allii tuberosi. In some embodiments, a fetus cervi powder is added in the submerged fermentation, so that the product is rich in plant polypeptides from traditional Chinese medicines. Fungus polysaccharide of the morel, animal polysaccharide from the fetus cervi powder and coordination compounds of the three polysaccharides have substantial effects on integrally enhancing immunity of the patients. The product provided by the invention can simultaneously treat principal and subordinate symptoms, and have no toxic or side effect, and fast effectiveness.

The invention discloses a Chinese traditional medicine capsule for treating lupus erythematosus and a preparation method of the Chinese traditional medicine capsule. The Chinese traditional medicine capsule for treating lupus erythematosus is characterized in that the raw materials comprise 15-45 parts by weight of peeled thunder god vine with removed roots, 15-45 parts by weight of leatherleaf milletia and 15-45 parts by weight of sargentgloryvine stem. The invention also provides a preparation method of the Chinese traditional medicine capsule for treating lupus erythematosus. According to the invention, the effective ingredients of the three raw material medicines can be effectively extracted, and the prepared capsule has a better effect than the original three-rattan mixture; and the quality can be effectively controlled, the capsule is convenient to take and carry, and the storage time is longer.

The Chinese medicine preparation for treating lupus erythematosus is prepared with nine kinds of Chinese medicinal materials including rhubarb, magnesium sulfate, skullcap root, chicken's gizzard membrane, red peony bark, etc. The recipe is composed based on Chinese medicine theory and the medicine is prepared through one modern advanced technological process. The medicine has obvious curative effect and less toxic side effect.

The invention relates to application of galectin-9, an active derivative thereof or a pharmaceutically acceptable salt thereof in preparation of drugs used for treating systemic lupus erythematosus or similar inflammatory diseases. The invention provides a method for treating systematic autoimmune diseases. The method comprises a step of administrating a therapeutically effective amount of galectin-9, the active derivative thereof or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to an object to be treated, and a systematic autoimmune disease is effectively treated or alleviated.

The invention belongs to the field of biotechnology, and discloses a function of a mini-chromosome maintenance complex component which plays an important role in immune dysfunction of systemic lupus erythematosus (SLE). The invention also discloses a method for detecting the level of the mini-chromosome maintenance complex component, and then for the auxiliary diagnosis of the systemic lupus erythematosus. The function of the mini-chromosome maintenance complex component in disease diagnosis and prevention of the systemic lupus erythematosus for the first time demonstrates that the mini-chromosome maintenance complex component family is closely related to the systemic lupus erythematosus, and the regulation and intervention of the mini-chromosome maintain protein level can improve the function of immune cells, and also provides a new drug target for the prevention and treatment of systemic lupus erythematosus.

The invention relates to a Chinese medicinal composition for treating systemic lupus erythematosus, and the Chinese medicinal composition can be used for effectively solving the problems that adverse effects of western medicaments are obvious and diseases easily relapse after withdrawal. According to the technical scheme, the composition is prepared from the following raw medicaments in parts by weight: 10 to 30 parts of buffalo horn, 10 to 30 parts of lithospermum, 5 to 20 parts of winged euonymus twig, 10 to 30 parts of gypsum rubrum, 10 to 40 parts of peony bark, 10 to 30 parts of sargentg loryvine stem, 10 to 20 parts of belvedere fruit, 5 to 10 parts of rhizoma paridis, 10 to 40 parts of Japanese dock root and 5 to 20 parts of piper cubeba. The Chinese medicinal composition has the effects of removing blood stasis, cooling blood, clearing heat, detoxifying, strengthening body resistance and eliminating evil, can be used for effectively improving the clinical symptoms of systemic lupus erythematosus patients and improving blood routine and main immunological indicators, and is an innovation of systemic lupus erythematosus treating medicaments.

The invention belongs to the technical field of traditional Chinese medicines and relates to a traditional Chinese medicine composition for treating systemic lupus erythematosus. The traditional Chinese medicine composition for treating systemic lupus erythematosus provided by the invention is prepared from the following raw materials in parts by weight: 10-12 parts of Chinese angelica, 5-8 parts of root of rehmannia, 6-9 parts of pseudo-ginseng, 3-5 parts of Radix Ophiopogonis, 10-12 parts of achyranthes root, 10-12 parts of lithospermum, 3-5 parts of Caulis Spatholobi, 3-5 parts of cortex moutan, 10-12 parts of Salvia miltiorrhiza, 8-10 parts of lucid ganoderma, 6-9 parts of glossy privet fruit and 10-12 parts of Codonopsis. The treatment medicine is obvious in curative effect, safe and reliable, and has wide clinical application prospect.

The invention discloses a Chinese patent medicine for treating discoid lupus erythematosus, which belongs to the technical field of treatment of skin diseases. The Chinese patent medicine is prepared from the following Chinese medicinal herbs in parts by weight: 10-20 parts of rehmanniae praeparatum, 15-25 parts of red paeony root, 15-25 parts of achyranthis bidentatae, 20-30 parts of dandelion, 20-30 parts of Chinese violet, 30-40 parts of red-rooted salvia, 15-25 parts of pollen, 15-25 parts of angelica, 15-25 parts of white paeony root, 15-25 parts of fructus forsythia, 15-25 parts of scutellaria, 10-15 parts of liquorice, 8-12 parts of dipsacus asperoides, 9-16 parts of scrophularia, 15-25 parts of cortex lycii radicis, 15-25 parts of Sophora flavescens, 10-20 parts of antelope horn, 10-20 parts of duckweed and 10-20 parts of rhizoma alismatis. Compared with the prior art, the Chinese patent medicine for treating the discoid lupus erythematosus has outstanding substantial characteristics and obvious advantages of removal of the diseases of patients, promotion of physical and psychological health, convenience for taking, quick therapeutic effect and no side effect.

The invention relates to the field of pharmaceutical chemistry, in particular to quinazolinone vasoinhibitors with general formulas I and II, and a preparation method and a medical application thereof, particularly use of the quinazolinone vasoinhibitors as medicines for preventing or treating tumors, retinopathy, rheumatic arthritis, diabetes, lupus erythematosus, chronic inflammation and other vascular proliferation diseases. The general formulas I and II are shown in the specifications.

The invention discloses a traditional Chinese medicine for treating lupus erythematosus. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 10-18 parts of white paeony root, 20-30 parts of radix rehmanniae preparata, 20-30 parts of astragalus membranaceus, 15-25 parts of cassia bark, 20-30 parts of largetrifoliolious bugbane rhizome, 25-35 parts of Chinese thorowax root, 10-20 parts of safflower, 12-18 parts of donkey-hide glue, 10-16 parts of raw oyster shell, 10-16 parts of raw turtle shell, 8-15 parts of raw tortoise plastron and 6-10 parts of white mulberry root-bark. The traditional Chinese medicine for treating lupus erythematosus, disclosed by the invention, adopts Chinese thorowax root as a main medicament, other auxiliary medicaments are matched, and the main medicament and the auxiliary medicaments act upon each other and have synergistic effects, so that the traditional Chinese medicine can play good roles in conditioning and tonifying the five internal organs, reinforcing qi and nourishing blood, soothing the liver and regulating qi circulation, and improving immunity, has a very good curative effect on lupus erythematosus, and is simple in raw material and convenient to take.

The invention discloses a kit used for helping to diagnose autoimmune diseases by a dextran specific antibody. Both an ELISA kit used for helping to diagnose systemic lupus erythematosus and an ELISA kit used for helping to diagnose rheumatoid arthritis which are discloses by the invention comprise antigens used for coating; the antigen used for coating can be Alpha-1 and 4-dextran, and astragalus polysaccharide is preferable; and the antigen used for coating can also be Alpha-1 and 6-dextran, and dextran is preferable. The kit can be used for helping to diagnose the systemic lupus erythematosus and the rheumatoid arthritis and has important application value.

The invention relates to a compound preparation for treating systemic lupus erythematosus. A grain of capsule of the compound preparation is prepared by combining 400 milligrams of ginsenoside and 10 to 20 milligrams of prednisone or 8 to 16 milligrams of meprednisone. The compound preparation not only enhances the biological effect of hormones, but also reduces the side effect of the hormones, so that the progress of the state of illness can be controlled more effectively. The compound preparation utilizes the effects of stress resistance, inflammatory resistance and the like of the ginsenoside used as main active ingredients of panax ginseng fully, has the two-way adjusting effect on the immunologic function and particularly has the synergistic effect with the prednisone, and is widely suitable for the treatment of autoimmune diseases.

The invention provides a traditional Chinese medicine formula for treating lupus erythematosus, which comprises the following components in parts by weight: Atractylodes atractylodes 25-35, white fresh skin 10-20, rhubarb charcoal 10-20, rose 7-15, lingxiaohua 7-15 , Salvia 7-15, leeches 8-16, Astragalus 8-16, Artemisia annua 10-20. The traditional Chinese medicine formula for treating lupus erythematosus provided by the invention has the advantages of good effect, low recurrence rate, treating both symptoms and root causes, and effectively relieving the patient's pain.